Adynxx, Inc.

Equities

ADYX

US00784D1037

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 08:01:06 05/12/2023 pm IST			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		-.--%	-.--%

2019	Adynxx, Inc. announced that it has received $0.45 million in funding	CI
2019	Adynxx, Inc. announced a financing transaction	CI

Adynxx, Inc announced that it expects to receive $13.97 million in funding

December 20, 2016

Adynxx, Inc announced that it will receive $13,973,150 in a round of funding on December 20, 2016. The company will issue equity in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.

Latest news about Adynxx, Inc.

Adynxx, Inc. announced that it has received $0.45 million in funding	17/19/17	CI
Adynxx, Inc. announced a financing transaction	30/19/30	CI
Adynxx, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2019	14/19/14	CI
Adynxx Receives NIH HEAL Initiative Funding Award for Development of Second Non-Opioid Pain Therapeutic	02/19/02	CI
Adynxx, Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2019	14/19/14	CI
Adynxx, Inc. Announces Board Changes	22/19/22	CI
Adynxx, Inc.(OTCPK:ADYX) dropped from S&P TMI Index	14/19/14	CI
Adynxx, Inc.(OTCPK:ADYX) dropped from S&P TMI Index	14/19/14	CI
Adynxx, Inc.(OTCPK:ADYX) dropped from NASDAQ Composite Index	12/19/12	CI
Adynxx, Inc. Announces Board Committee Appointments	01/19/01	CI
Adynxx, Inc. Announces Management Changes	10/19/10	CI
Adynxx, Inc.(OTCPK:ADYX) added to NASDAQ Composite Index	06/19/06	CI
Adynxx, Inc.(OTCPK:ADYX) added to S&P TMI Index	06/19/06	CI
Adynxx, Inc. completed the acquisition of Alliqua BioMedical, Inc. in a reverse merger transaction.	03/19/03	CI
Adynxx Provides Clinical Updates	22/19/22	CI
Adynxx, Inc. Announces Receipt of Notice of Award for $5.7 Million in Federal Grant Funding	14/18/14	CI
Adynxx and twoXAR Form Collaboration to Discover and Develop Treatments for Endometriosis	15/18/15	CI
Adynxx, Inc. entered into a definitive merger agreement to acquire Alliqua BioMedical, Inc. in a reverse merger transaction.	12/18/12	CI
Adynxx Completes Enrollment in ADYX-004, a Phase 2 Study of Brivoligide	04/17/04	CI
Adynxx, Inc. Initiates ADYX-004, a Phase 2 Study of AYX1, Lead Compound for the Treatment of Post-Surgical Pain	01/17/01	CI
Adynxx, Inc announced that it has received $16 million in funding from TPG Biotech, Domain Associates, L.L.C., and another investor	09/17/09	CI
Adynxx, Inc announced that it expects to receive $13.97 million in funding	20/16/20	CI
Adynxx Reports Positive Results for Phase 2b Study of AYX1	11/15/11	CI
Adynxx Initiates Phase 2 Dose-Ranging Study of AYX1	16/14/16	CI
Adynxx Completes Patient Enrollment in Phase 2 Clinical Study of its Lead Product Candidate AYX1	05/13/05	CI

Chart Adynxx, Inc.

Duration

Period

More charts

Company Profile

Adynxx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to market disease-modifying products to address unmet needs in the treatment of pain and inflammation. The Company has leveraged its AYX platform of proprietary transcription factor decoys to identify and develop product candidates designed to modify the course of pain. Its product pipeline includes Brivoligide for postoperative pain and AYX2 for chronic pain. Brivoligide is a transcription factor decoy specifically designed to inhibit the function of transcription factor Early Growth Response 1 (EGR1), in the dorsal root ganglia (DRG), and spinal cord when administered at the time of surgery. Its second product candidate, AYX2, is a transcription factor decoy targeting the activity of specific members of the KLF family of transcription factors, including KLF6, KLF9 and KLF15.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ADYNXX, INC.	-.--%	5
MODERNA, INC.	+59.67%	6.26TCr
IQVIA HOLDINGS INC.	-2.76%	4.12TCr
LONZA GROUP AG	+44.70%	4.03TCr
CELLTRION, INC.	-8.29%	2.79TCr
ICON PUBLIC LIMITED COMPANY	+12.94%	2.62TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.99%	1.91TCr
BIO-TECHNE CORPORATION	+5.87%	1.31TCr
UNITED THERAPEUTICS CORPORATION	+24.86%	1.23TCr
MEDPACE HOLDINGS, INC.	+27.45%	1.21TCr

Other Biotechnology & Medical Research